Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach

OBJECTIVE: This study evaluated the cost effectiveness of using Stockholm 3 (STHLM3) testing compared to the prostate-specific antigen (PSA) test in the diagnostic pathway for prostate cancer. METHODS: We created a decision tree model for PSA (current standard) and STHLM3 (new alternative). Cost eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Risør, Bettina Wulff, Tayyari Dehbarez, Nasrin, Fredsøe, Jacob, Sørensen, Karina Dalsgaard, Pedersen, Bodil Ginnerup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596577/
https://www.ncbi.nlm.nih.gov/pubmed/35934771
http://dx.doi.org/10.1007/s40258-022-00741-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596577/
https://www.ncbi.nlm.nih.gov/pubmed/35934771
http://dx.doi.org/10.1007/s40258-022-00741-0

Ejemplares similares